Sign In
Buy QURE
$29.88
+3.12 (+11.66%)
At Close: Jun 03, 2026
Raymond James Top Health Care Picks Crushing S&P 500: 4 Stocks to Buy Now
07:59am, Thursday, 03'rd Dec 2020
The health care sector as a whole has been a top performer this year, and there is every reason to believe that strong performance will carry through to 2021.
uniQure to Participate in Multiple Upcoming Industry Conferences in December
07:05am, Wednesday, 02'nd Dec 2020
LEXINGTON, Mass and AMSTERDAM, Dec. 02, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,
~ Strong P resence at ASH Featuring Five P resentations , Including Late-Breaking Oral Presentation on HOPE-B Pivotal Trial ~
UniQure Rallies On Positive Late-Stage Data For Hemophilia B Gene Therapy
01:22pm, Thursday, 19'th Nov 2020
UniQure NV (NASDAQ: QURE) shares were advancing to four-month highs Thursday in reaction to a positive clinical data readout. What Happened: The Lexington, Massachusetts-based company announced posit
~ Phase III study in 54 patients met primary endpoint with mean Factor IX activity of 37% of normal at 26 weeks ~
uniQure Announces Clinical Data Presentations at the 62nd American Society of Hematology (ASH) Annual Meeting
10:46am, Wednesday, 04'th Nov 2020
LEXINGTON, Mass. and AMSTERDAM, Nov. 04, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,
uniQure to Participate in Multiple Upcoming Industry Conferences in November
07:05am, Wednesday, 04'th Nov 2020
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 04, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with seve
uniQure Announces Third Quarter 2020 Financial Results and Highlights Recent Company Progress
07:05am, Tuesday, 27'th Oct 2020
~ Enrolled First Four Patients in Phase I/II Clinical Trial of AMT-130 in Huntington's Disease ~
5 Healthcare Stocks the Experts at Aquilo Capital Management Are Buying (1 Has Gained 88% This Month)
05:28pm, Monday, 26'th Oct 2020
Marc Schneidman's Aquilo Capital Management is a San Francisco-based, healthcare-focused long/short hedge fund that was founded in 2010. The fund uses CIO Schneidman's 20 years of industry expertise i
